VF Corp. Names Matt Puckett CFO, Succeeding Scott Roe

VF Corp. (VFC), an apparel, footwear and accessories company, announced Thursday that it has appointed Matt Puckett to the position of Executive Vice President and Chief Financial Officer.

Puckett succeeds Scott Roe, who announced his retirement from VF to pursue other opportunities after 25 years with the company, the last six of which were in the CFO position.

Roe will remain with VF through the end of May to close out the company's fiscal year 2021. Puckett will assume the CFO position upon Roe's departure from VF.

In his new role, Puckett, 47, will report to VF's CEO, Steve Rendle, and serve on the company's Executive Leadership Team.

He has been serving as VF's Vice President, Global Financial Planning & Analysis.

He joined VF in 2001 as a Senior Accountant in the finance organization. In the following years, Puckett held a series of finance roles with increasing responsibility, including being appointed in 2009 as CFO of VF's Sportswear Coalition, which comprised the Nautica and Kipling brands.

Immediately following VF's 2011 acquisition of the Timberland brand, Puckett was appointed CFO of Timberland. In 2015, he was named CFO of VF International.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT